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Introduction 
The guideline group was selected to be representative of UK-based medical experts with 
an interest in myeloproliferative neoplasms and eosinophilia. PubMed and EMBASE 
were searched systematically for publications in English until August 2015 using the key 
words eosinophilia, hypereosinophilia, eosinophilic leukaemia and HES. The writing 
group produced the draft guideline which was subsequently revised by consensus by 
members of the General Haematology and Haemato-oncology Task Forces of the British 
Committee for Standards in Haematology. The guideline was then reviewed by a 
sounding board of UK haematologists and representatives from the Nordic MPN Study 
Group, the British Committee for Standards in Haematology (BCSH) and the British 
Society for Haematology (BSH) Committee and comments were incorporated where 
appropriate. The ‘GRADE’ system was used to quote levels and grades of evidence, 
details of which can be found in Table I. The objective of this guideline is to provide 
healthcare professionals with clear guidance on the investigation and management of 
eosinophilia.
Guideline Update 
There is no previous BCSH guideline for this topic. 
Aim 
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The purpose of this guideline is to provide a practical approach to the investigation and 
management of eosinophilia. 
Key recommendations 
 The underlying cause of eosinophilia should be sought and possible 
eosinophil-associated end organ damage should be evaluated (Grade 1B) 
Assessment of underlying cause 
 A detailed medical history should be taken and a thorough physical 
examination should be performed (Grade 1C).  
The history should include:  
o assessment for allergic disorders, skin rashes and cardiorespiratory, 
gastrointestinal and constitutional symptoms. 
o a detailed travel history, particularly for tropical travel; travel even in 
the remote past may be relevant. 
o a detailed drug history. 
 All patients should have a full blood count, blood film examination and 
routine tests of renal and liver function, a bone profile, lactate 
dehydrogenase and erythrocyte sedimentation rate and/or C-reactive protein 
(Grade 1C) 
 Patients who are otherwise well with mild to moderate eosinophilia between 
0.5 and 1.5 × 109/l may not require further testing. Patients with systemic 
symptoms and those with persistent eosinophilia (at least 1.5 × 109/l), 
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irrespective of suspected organ damage, should be considered for additional 
testing for an underlying cause  
 Specific causes of reactive eosinophilia, based on clinical suspicion, should be 
confirmed or excluded at an early stage by appropriate testing (Grade 1C). 
 Patients with an eosinophil count of at least 1.5 × 109/l with no obvious cause 
should be investigated for a possible haematological neoplasm with clonal 
eosinophilia, initially by peripheral blood analysis for FIP1L1-PDGFRA by 
fluorescence in situ hybridisation (FISH) or nested reverse transcriptase 
polymerase chain reaction (RT-PCR) (Grade 1C). 
 Serum tryptase estimation should be performed if the differential diagnosis 
includes chronic eosinophilic leukaemia or systemic mastocytosis (Grade 1B).  
 In the absence of an identifiable cause and with negative peripheral blood 
analysis for FIP1L1-PDGFRA by FISH or nested RT-PCR, a bone marrow 
aspirate, trephine biopsy and cytogenetic analysis should be performed; the 
possibility of an underlying lymphoma or of the lymphocytic variant of 
hypereosinophilic syndrome should be evaluated, including consideration of 
immunophenotyping of peripheral blood and bone marrow lymphocytes and 
analysis for T-cell receptor gene rearrangement (Grade 1C). The possibility 
of systemic mastocytosis or other myeloid neoplasm should be considered. 
Assessment for possible eosinophil-associated end organ damage 
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 End organ damage should be assessed using chest radiography and/or 
computed tomography (CT) of the thorax, echocardiography, serum 
troponin T and pulmonary function testing. (Grade 1C). 
 An unprovoked thromboembolic event should be recognised as a possible 
manifestation of eosinophil-associated tissue damage (Grade 2C). 
 In patients with end organ damage, the frequency of further serial 
evaluations of organ function should be determined by the severity and 
extent of organ compromise and/or by worsening of the eosinophilia (Grade 
2C). 
Emergency treatment  
 Patients requiring emergency treatment for severe or life-threatening 
eosinophilia should receive high-dose corticosteroids (Grade 1B). 
 Patients receiving corticosteroids, in whom there is a risk of strongyloides 
infection, should receive concomitant ivermectin to prevent potentially fatal 
hyperinfection (Grade 1B) 
Treatment of clonal eosinophilia 
 Patients with clonal eosinophilia with FIP1L1-PDGFRA (including patients 
presenting with acute leukaemia), should be treated with low dose imatinib 
(Grade 1B). 
 Patients with clonal eosinophilia with PDGFRB rearrangement or ETV6-
ABL1 fusion should receive standard dose imatinib (Grade 1B). 
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 Patients with clonal eosinophilia with ETV6-FLT3 fusion should be 
considered for sunitinib or sorafenib therapy (Grade 2B) 
 Patients with clonal eosinophilia with JAK2 rearrangement should be 
considered for ruxolitinib therapy (Grade 2B) 
 Patients with acute myeloid leukaemia (AML) with clonal eosinophilia and 
no molecular or cytogenetic abnormality suggesting likely response to a 
tyrosine kinase inhibitor  should be offered standard AML induction therapy 
(Grade 1A). 
 Patient with other haematological neoplasms with clonal eosinophilia should 
have treatment directed at management of the neoplasm. If there is organ 
damage or dysfunction relating to the eosinophilia, treatment with 
corticosteroids should also be given (Grade 1C). 
Treatment of lymphocytic variant of hypereosinophilic syndrome 
 Patients with the lymphocytic variant of hypereosinophilic syndrome (HES) 
can be managed in the same manner as idiopathic HES (grade 2B) 
Treatment of idiopathic hypereosinophilic syndrome 
 Patients with idiopathic HES should be treated in the first instance with 
corticosteroids (see emergency treatment above). 
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 Patients with idiopathic HES who do not respond adequately to 
corticosteroids, or who require prolonged corticosteroid therapy, or who are 
intolerant of corticosteroids, should be considered for a short trial (4‒6 weeks) 
of imatinib, immunomodulatory agents (interferon alpha, ciclosporin or 
azathioprine), myelosuppressive therapy (hydroxycarbamide) or monoclonal 
antibody therapy with mepolizumab (anti-interleukin 5), the latter 
preferably as part of a clinical trial (Grade 2B).  
 Alemtuzumab, an anti-CD52 monoclonal antibody, should be considered for 
patients with severe idiopathic HES unresponsive to other therapies, and 
may be useful in patients with idiopathic HES-associated cardiac and 
cerebral dysfunction. (Grade 2B) 
Role of haemopoietic stem cell transplantation (HSCT) 
 HSCT should be considered for cases with clonal eosinophilia with FGFR1
rearrangement, patients with chronic eosinophilic leukaemia, not otherwise 
specified and those HES patients refractory to or intolerant of both 
conventional tyrosine kinase inhibitor (TKI) therapy and experimental 
medical therapy, where available, or who display progressive end organ 
damage. (Grade 2C) 
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Definitions 
Eosinophilia is defined as an elevation of the eosinophil count above levels observed in 
healthy subjects, usually taken as above 0.5 × 109/l. Eosinophil counts are higher in 
neonates than in adults and the values gradually fall in the elderly. There is no sex or 
ethnic variation in the eosinophil count. Definitions of hypereosinophilia (HE) and the 
hypereosinophilic syndrome (HES) are based on the proposal by Chusid et al (Chusid et 
al, 1975) that required eosinophils to be 1.5 × 109/l or greater in the hypereosinophilic 
syndrome with evidence of eosinophil-mediated organ damage or dysfunction after 
exclusion of the other potential causes for the organ damage. This criterion was 
subsequently accepted in the World Health Organization (WHO) classification of chronic 
eosinophilic leukaemia, not otherwise specified (CEL, NOS) (Bain et al, 2008). 
Biology 
The normal bone marrow contains between 1% and 6% eosinophils and these produce an 
eosinophil count in the peripheral blood of 0.05–0.5 × 109/l (Valent et al, 2012). 
Eosinophil production in the marrow is tightly controlled by a network of transcription 
factors (McNagny & Graf 2002) and is driven by various cytokines, principally 
interleukin (IL)-5, IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
produced by activated T lymphocytes, stromal cells and mast cells, triggering 
differentiation and activation (Ackerman & Bochner 2007). Such cytokines are also the 
main drivers in reactive eosinophilia in contrast to clonal eosinophilia where tyrosine 
kinase fusions are common, typically involving the genes coding for platelet-derived 
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growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta 
(PDGFRB) or fibroblast growth factor receptor 1 (FGFR1) (Gotlib et al, 2006).  
Under normal conditions, eosinophils may also be found in lymphoid organs and the 
mucosa of the gastrointestinal tract and uterus but very rarely in other tissues.  However, 
prolonged or marked activation of eosinophils may cause migration into non-native 
tissues such as the skin, heart and lung where they may cause end-organ damage 
principally through the induction of thrombosis and fibrosis (Gleich 2000). 
Epidemiology 
Primary and idiopathic eosinophil disorders are rare and probably under-diagnosed 
conditions. A large population based study in a general practice setting from Copenhagen 
demonstrated an incidence of eosinophilia (defined as a count of at least 0.5 × 109/l) of 
4% (Andersen et al, 2015).
Causes of Eosinophilia 
The causes of eosinophilia are numerous and are conventionally divided into three main 
categories – secondary (reactive), primary and idiopathic – as indicated in Table II. These 
are discussed below. HES predominantly affects males, with an estimated male-to-female 
ratio ranging up to 9 : 1 (Weller & Bubley 1994). This is partly explained by the fact that 
the FIP1L1-PDGFRA fusion gene occurs almost exclusively in males. 
Secondary (reactive) eosinophilia 
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These form the majority of cases of eosinophilia. 
Allergic Disorders 
Allergic disorders such as atopic dermatitis, asthma and seasonal allergic disorders 
(rhinitis/hayfever) can result in a cytokine-driven non-clonal eosinophilia which is 
usually mild (less than 1.5 × 109/l) with the degree of blood eosinophilia and tissue 
infiltration generally correlating with the severity of the disease (Horn et al, 1975). The 
eosinophilia usually resolves with control of the underlying condition.  
Dermatological causes (non-allergic) 
Wells syndrome (eosinophilic cellulitis) is a recurring granulomatous dermatitis with 
eosinophilia (Wells 1971) characterised by (i) sudden onset annular or circinate 
erythematous-oedematous patches that rapidly evolve to morphoea-like slate-blue 
plaques, (ii) a histological appearance characterized by the presence of 'flame figures' and 
(iii) an inconstant blood eosinophilia. Similar histological appearances can be seen in 
other dermatological conditions but these can often be discriminated clinically. Wells 
variants have been described (El-Khalawany et al, 2013) as well as associations with 
other disorders including connective tissue disease (Yin & Xie 2012). 
Drug-induced eosinophilia
Drug hypersensitivity should always be considered as a cause for unexplained 
eosinophilia. The list of agents is extensive and includes dietary supplements and herbal 
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remedies (Klion 2009). The clinical manifestations associated with drug-induced 
eosinophilia range from asymptomatic to life-threatening (Klion 2009). Rarely a drug 
reaction with eosinophilia and systemic symptoms (DRESS syndrome) occurs 3‒6 weeks 
after the introduction of a new drug. This syndrome is characterised by a triad of a skin 
eruption, fever and internal organ involvement (lung, liver, kidneys, lymph nodes or heart)
(Dong et al, 2014; Sultan et al, 2015). Drug-induced vasculitis and eosinophilia is also 
reported, manifesting with purpura, arthralgia and myalgia with possible kidney and lung 
involvement (Roujeau et al, 2014). 
Infectious diseases 
A detailed review of infectious causes of eosinophilia has recently been published 
(O'Connell & Nutman 2015). Important infective agents and their diagnostic tests are 
outlined in Table III. The British Infection Society and the Hospital for Tropical Diseases 
have published UK recommendations for the investigation of eosinophilia in patients 
with a tropical travel history (Checkley et al, 2010).  
Gastrointestinal disorders
Primary gastrointestinal disorders are rarely associated with gastrointestinal tissue 
eosinophilia with or without peripheral blood eosinophilia. Table IV highlights the main 
disorders that need to be considered in the differential diagnosis.  
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Vasculitides
Polyarteritis nodosa (PAN) results in inflammation and injury to medium-sized and small 
arteries leading to ischaemia or haemorrhage in a variety of tissues and organs, though 
the kidneys are usually spared. Renal sparing and negative antineutrophil cytoplasmic 
antibodies (ANCA) are useful in differentiating PAN from other systemic necrotizing 
vasculitides (Hernandez-Rodriguez et al, 2014). Eosinophilia is occasionally seen but, 
when present, eosinophilic granulomatosis with polyangiitis  must be considered (Watts
et al, 2007). 
Eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss syndrome): EGPA
can present with a variety of clinicopathological features depending on the organs 
involved:  allergic rhinitis, acute hepatitis, diarrhoea (mesenteric ischaemia), restrictive 
cardiomyopathy, peripheral neuropathy, skin lesions and, rarely, renal disease. ANCA is 
useful to support the diagnosis and is positive in approximately two-thirds of patients –
mostly perinuclear ANCA (p-ANCA) against myeloperoxidase (MPO). The diagnosis is 
confirmed by tissue biopsy. 
Rheumatological Diseases 
Systemic lupus erythematosus (SLE): eosinophilia is not uncommonly described in 
individual case reports but there are no systematic studies on the incidence and severity 
of eosinophilia in SLE and eosinophilia does not form one of the diagnostic criteria for 
the condition (Petri et al, 2012).  
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Eosinophilic fasciitis (Shulman disease): this  is a rare scleroderma-like syndrome of 
unknown cause, thought to be immune mediated with resultant painful swelling and 
progressive induration and thickening of skin/soft tissues of limbs and trunk. Laboratory 
findings are those of a peripheral blood eosinophilia, hypergammaglobulinaemia and 
elevated erythrocyte sedimentation rate (ESR). There are no universally accepted 
diagnostic criteria but in a recent review (Pinal-Fernandez et al, 2014) peripheral blood 
eosinophilia formed one of four minor criteria for the diagnosis. There is an association 
with aplastic anaemia (De Masson et al, 2013). 
Rheumatoid arthritis (RA): a recent prospective French study showed that approximately 
3% of patients with RA have an eosinophilia, which is usually mild and transient 
(Guellec et al, 2015). Although this prevalence does not differ from that of the Danish 
population study, defined in the same manner (Andersen et al, 2015), eosinophilia did 
appear to predict a poorer response to disease-modifying antirheumatic drug use after 3 
years (Guellec et al, 2015). A smaller Argentinian study demonstrated a 7% prevalence 
of eosinophilia amongst RA patients, but in all these cases a parasitic cause for the 
eosinophilia was subsequently demonstrated (Chiardola et al, 2008). 
Respiratory disease 
Löffler disease: Löffler first described this transient pulmonary reaction with 
reticulonodular shadowing on chest radiology associated with a peripheral blood 
eosinophilia in 1932. Patients present with a low grade fever and a cough for 7‒10 days, 
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which is usually due to an allergic reaction in the alveoli as a result of a parasitic 
infection (see Infectious disease) or medications (See Drug-Induced). Occasionally 
patients present with skin lesions. The onset of symptoms is typically 2‒3 weeks 
following exposure to parasites and 3‒4 days following ingestion of medication. This is 
usually a self limiting disease with symptoms subsiding within 3‒4 weeks of eliminating 
the causal agent. The differential diagnosis is allergic bronchopulmonary aspergillosis 
and asthma. 
Allergic bronchopulmonary aspergillosis is caused by hypersensitivity to Aspergillus 
fumigatus and results in uncontrolled asthma and recurrent pulmonary infiltrates which 
can progress to bronchiectasis and pulmonary fibrosis (Agarwal et al, 2013). Diagnostic 
criteria include a history of asthma or cystic fibrosis, elevated aspergillus-specific 
immunoglobulin (Ig) E and IgG, elevated serum IgE (1000 ng/ml or > 417 iu/ml), wheal-
and-flare skin reaction to aspergillus antigen and an eosinophil count greater than 1.0 × 
109/l.  
Sarcoidosis: there is no diagnostic test for sarcoidosis though a mild peripheral blood 
eosinophilia, raised serum angiotensin converting enzyme (ACE) level and a tissue 
biopsy demonstrating the presence of non-caseating granulomas in affected organs 
suggests the diagnosis.  
Neoplastic disorders with secondary non-clonal eosinophilia  
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Solid tumours: a range of non-haematological neoplasms have been reported to cause 
reactive eosinophilia, with a prevalence of 0.5% to 7% (Montgomery et al, 2013).  The 
presence of eosinophilia is often associated with more advanced metastatic disease. In 
cases of unexplained eosinophilia, careful clinical evaluation and radiological studies 
should be carried out to exclude underlying occult malignancy (Klion 2009). 
Lymphoproliferative disorders: reactive eosinophilia occurs in a broad spectrum of B- 
and T-cell lymphoproliferative disorders. In Hodgkin lymphoma the prevalence of 
eosinophilia is 15% (Vaughan Hudson et al, 1987) and in non-Hodgkin lymphoma 
prevalence ranges from 2% to 20% (Montgomery et al, 2013) with a higher prevalence in 
T-cell than B-cell lymphomas. Reactive eosinophilia can occur in acute lymphoblastic 
leukaemia/lymphoma (Grimaldi & Meeker 1989). In the case of B-lineage acute 
lymphoblastic leukaemia (ALL) with t(5;14)(q31.1;q32.1), it results from dysregulation 
of the IL3 gene by proximity to the IGH locus. When eosinophils are part of the 
neoplastic clone the eosinophilia is primary rather than reactive and the case falls into the 
group of haematological neoplasms with clonal eosinophilia.  
Lymphocytic variant HES (L-HES) 
L-HES is caused by an expansion of demonstrably clonal or phenotypically aberrant T-
lymphoid cells in the peripheral blood with a secondary, reactive eosinophilia (Simon et 
al, 1999), without overt lymphoproliferative disease. Such abnormal T-cell populations 
have been reported to be present in 17% to 27% of otherwise unexplained HES (Ogbogu
et al, 2009; Simon et al, 1999). There are no current consensus diagnostic criteria and 
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diagnosis rests on demonstration of an abnormal T-cell population by flow cytometry, 
with a broad range of phenotypes reported including CD3-CD4+, CD3+CD4-CD8- and 
CD3+CD4+CD7- (Roufosse 2009). Some cases of L-HES harbour T-cell receptor gene 
rearrangement (Simon et al, 1999), but this alone is insufficient to make the diagnosis of 
L-HES in the absence of phenotypically abnormal T cells (Roufosse 2009). Clinical 
manifestations of disease in L-HES are typically cutaneous (Simon et al, 1999). 
Miscellaneous Causes 
Atheroembolic disease: cholesterol atheroembolic disease develops as a consequence of 
cholesterol microembolisation following rupture of atheromatous aortic plaques after 
arterial catheterisation procedures, vascular surgery or following anticoagulant or 
thrombolytic therapy. A transient eosinophilia has been reported in the acute phase of the 
illness (Kasinath & Lewis 1987; Scolari et al, 2007), thought to be driven by increased 
IL-5 production by activated T cells at the surface of emboli (Cogan et al, 1995). The 
diagnosis is usually confirmed by biopsy of an affected organ.  
Graft-Versus-Host Disease: eosinophilia can be a feature of both acute and chronic graft-
versus-host disease (GVHD) following allogeneic haematopoietic stem cell 
transplantation (HSCT) (Ahmad et al, 2011; Imahashi et al, 2010; Jacobsohn et al, 2004) 
although the mechanisms underlying this are unclear. Conflicting data exist regarding the 
prognostic significance of the eosinophilia (Ahmad et al, 2011; Imahashi et al, 2010). 
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Gleich's syndrome: this rare disease was first described in 1984 (Gleich et al, 1984) and 
is characterised by episodic angio-oedema with eosinophilia. It is associated with raised 
IgM and C1 esterase levels are normal. There is no evidence that this syndrome leads to 
end organ damage. Steroids may reduce the severity of attacks. 
Clonal eosinophilia  
A number of haematological neoplasms may be accompanied by an eosinophilia in which 
the eosinophils are part of the neoplastic clone, and the eosinophilia is thus primary. 
These are listed in Table II. 
Clonal eosinophilia should be suspected in patients who present with unexplained 
isolated eosinophilia, possibly representing chronic eosinophilic leukaemia (CEL), or 
with haematological features consistent with chronic myelomonocytic leukaemia with 
eosinophilia (CMML-Eo) or atypical chronic myeloid leukaemia with eosinophilia 
(aCML-Eo). The neoplastic disorders to be considered in these patients include those 
with JAK2V617, KITD816V or rearrangement of PDGFRA, PDGFRB or FGFR1 (Bain 
2008), PCM1-JAK2 (Bain & Ahmad 2014) and, rarely, BCR-JAK2 (Bain & Ahmad 
2014), ETV6-JAK2 (Bain & Ahmad 2014), ETV6-ABL1 (Nand et al, 2009) or ETV6-
FLT3 (Walz et al, 2011). Patients with BCR-ABL1-positive chronic myelogenous 
leukaemia in chronic phase do not have disproportionate eosinophilia, although the 
eosinophils are clonal; however predominant eosinophilia can occur at the time of disease 
acceleration or blast transformation.  
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Rarely patients with acute myeloid leukaemia associated with t(8;21)(q22;q22.1) or 
inv(16)(p13.1q22) present with prominent peripheral blood eosinophilia (AML-Eo).  
Apparent AML-Eo can also represent transformation of a myeloproliferative neoplasm 
(MPN) with rearrangement of PDGFRA, PDGFRB or FGFR1. 
Patients who present with ALL with eosinophilia may have either reactive eosinophilia or 
a leukaemia arising in a pluripotent lymphoid-myeloid stem cell in which the eosinophils 
are clonal. T-ALL/T lymphoblastic lymphoma with associated clonal eosinophilia can 
occur with PDGFRA and FGFR1 rearrangements and with ETV6-FLT3; a small number 
of cases of T lymphoblastic lymphoma (Chmielecki et al, 2012; Ondrejka et al, 2014) or 
unspecified lymphoid blast phase (Metzgeroth et al, 2013) have also been reported in 
MPNs with PDGFRB rearrangement.  Rarely B-ALL/B lymphoblastic lymphoma
transformation is seen in association with PDGFRA rearrangement (Trempat et al, 2003).  
B-ALL/B lymphoblastic lymphoma occurs more often in association with FGFR1
rearrangement and mixed phenotype acute monoblastic/precursor-B ALL (Yamamoto et 
al, 2006) has also been reported in this context. Cases with PCM1-JAK2 can suffer a B 
lymphoblastic transformation. 
Eosinophilia can be a feature of systemic mastocytosis when it can be postulated that the 
eosinophilia may be either cytokine driven, clonal or a combination of the two.  
Chronic eosinophilic leukaemia, not otherwise specified is, by definition, BCR-ABL1-
negative without rearrangement of PDGFRA, PDGFRB or FGFR1 (Bain et al, 2008). 
Cases with PCM1-JAK2, ETV6-JAK2 or BCR-JAK2 should also be excluded. The 
eosinophil count must be at least 1.5 × 109/l and, to make a distinction from AML-Eo, 
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blast cells must be less that 20% in both the peripheral blood and bone marrow and t(8;21) 
and inv(16) must be absent. There may be some increase in neutrophils and monocytes or, 
occasionally, basophils. For the condition to be recognised as leukaemic in nature there 
must be an increase of blast cells in the blood or marrow or cytogenetic or other evidence 
of clonality. Cytogenetic abnormalities observed have included trisomy 8 and i(17q). 
CEL, not otherwise specified (CEL, NOS) is a rare and aggressive disorder associated 
with a median survival of 20 months and a high rate of acute transformation (Helbig et al,
2012; Klion 2011).
Idiopathic hypereosinophilia and the idiopathic hypereosinophilic syndrome  
Idiopathic hypereosinophilia (idiopathic HE) and the idiopathic hypereosinophilic 
syndrome (idiopathic HES) are diagnoses of exclusion in patients who have been 
appropriately assessed with a detailed history, physical examination and thorough 
investigation without any cause being found. Both are defined by an eosinophil count of 
1.5 × 109/l or more (Chusid et al, 1975) with, in the case of idiopathic HES, there also 
being tissue damage. Organ systems involved include the heart, lungs, skin, peripheral 
and central nervous systems and gastrointestinal tract. Thromboembolic complications 
are common. Some cases are likely to represent a reactive condition consequent on an 
unrecognised underlying cause. Others cases may represent eosinophilic leukaemia which 
is sometimes confirmed on follow up when blast transformation occurs.   
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Evaluation of patients presenting with eosinophilia 
The evaluation of eosinophilia is centred on investigating for a possible underlying cause 
and assessing possible eosinophil-associated end organ damage or dysfunction. These 
investigations are usually performed in parallel. 
The diagnostic process begins with a detailed medical history involving the assessment 
for allergic disorders such as asthma, eczema, urticaria and hay fever.  A history of skin 
rashes or lymphadenopathy should be sought. Cardiorespiratory and gastrointestinal 
symptoms should be evaluated. Constitutional symptoms should be noted including fever, 
drenching night sweats, weight loss, pruritus and alcohol-induced pain. A detailed travel 
history, particularly of tropical travel, should be taken; even travel in the remote past may 
be relevant. A detailed drug history should be taken. 
A thorough physical examination should be performed. 
Initially, all patients should have a full blood count performed and a blood film 
examined. This is to verify the eosinophil count as hypogranular eosinophils may not be 
counted accurately by automated counters. The arbitrary eosinophil count accepted for a 
diagnosis of CEL, NOS (Bain et al, 2008) and idiopathic HES (Chusid et al, 1975) is a 
count of at least 1.5 × 109/l (but molecular analysis permits certain entities to be 
diagnosed with a lower count).  The blood film may indicate an alternative cause for the 
eosinophilia, such as parasitic disease, or may show morphological evidence of an 
underlying haematological neoplasm including blast cells, neutrophilia and left shift, 
monocytosis, basophilia, dysplastic features or circulating lymphoma cells or mast cells. 
21 
The cytological features of eosinophils are not helpful in the differential diagnosis since 
striking abnormalities can occur in reactive eosinophilia and sometimes clonal 
eosinophils are cytologically fairly normal. 
Routine tests should be performed for renal, liver and bone profile, lactate dehydrogenase 
and ESR and/or C-reactive protein (CRP). 
Further testing is dependent on the suspected diagnosis based on the history, examination 
and the results of these initial investigations, and on the degree of clinical urgency. 
Suggested investigations are outlined in Table V. In patients who are otherwise well with 
mild to moderate eosinophilia between 0.5 and 1.5 × 109/l, further testing may not be 
indicated. Patients with systemic symptoms or those with persistent eosinophilia (at least 
1.5 × 109/l), with or without suspected organ damage, should be considered for additional 
testing for primary and secondary causes of eosinophilia and for evaluation of organ 
damage.  
Secondary (reactive) causes of eosinophilia should be confirmed or excluded at an early 
stage. In patients with an eosinophilia of at least 1.5 × 109/l with no obvious secondary 
cause, a haematological neoplasm with clonal eosinophilia should be considered. In a 
non-urgent situation, it is prudent to do the least invasive tests first with peripheral blood 
analysis for FIP1L1-PDGFRA by fluorescence in situ hybridisation (FISH) or nested 
reverse transcriptase polymerase chain reaction (RT-PCR). Serum tryptase estimation is 
indicated if the differential diagnosis includes CEL or systemic mastocytosis. Otherwise, 
a bone marrow aspirate, trephine biopsy and cytogenetic analysis should be performed. 
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Morphological assessment of the marrow is vital for exclusion of haematological and 
non-haematological malignancy. If serum tryptase is elevated, a diagnosis of systemic 
mastocytosis should be considered and molecular analysis for KIT on a bone marrow 
aspirate should be performed. However it should be noted that serum tryptase is also 
often elevated in patients with CEL with FIP1L1-PDGFRA who may also have increased 
bone marrow mast cells; because of their sensitivity to imatinib, it is very important that 
such cases are not misdiagnosed as systemic mastocytosis. In addition, occasional cases 
of unexplained eosinophilia may test positive for JAK2V617F (Schwaab et al, 2015). 
Abnormalities that are particularly sought on cytogenetic and molecular analysis and 
their clinical significance are summarised in Table VI.  It is important to stress that 
almost all tyrosine kinase fusions apart from FIP1L1-PDGFRA are associated with 
visible cytogenetic rearrangements and therefore we recommend bone marrow 
cytogenetic analysis for cases with a suspected underling MPN. Break-apart FISH 
analysis for specific loci may be used as an alternative but may be a relatively expensive 
approach. Any suspected fusion should be confirmed by RT-PCR and sequencing to 
ensure that targeted therapy is used appropriately and to facilitate subsequent molecular 
monitoring. 
Key recommendations 
 The underlying cause of eosinophilia should be sought and possible 
eosinophil-associated end organ damage should be evaluated (Grade 1B) 
Assessment of underlying cause 
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 A detailed medical history should be taken and a thorough physical 
examination should be performed (Grade 1C).  
The history should include:  
o assessment for allergic disorders, skin rashes and cardiorespiratory, 
gastrointestinal and constitutional symptoms. 
o a detailed travel history, particularly for tropical travel; travel even in 
the remote past may be relevant. 
o a detailed drug history. 
 All patients should have a full blood count, blood film examination and 
routine tests of renal and liver function, a bone profile, lactate 
dehydrogenase and erythrocyte sedimentation rate and/or C-reactive protein 
(Grade 1C) 
 Patients who are otherwise well with mild to moderate eosinophilia between 
0.5 and 1.5 × 109/l may not require further testing. Patients with systemic 
symptoms and those with persistent eosinophilia (at least 1.5 × 109/l), 
irrespective of suspected organ damage, should be considered for additional 
testing for an underlying cause  
 Specific causes of reactive eosinophilia, based on clinical suspicion, should be 
confirmed or excluded at an early stage by appropriate testing (Grade 1C). 
 Patients with an eosinophil count of at least 1.5 × 109/l with no obvious cause 
should be investigated for a possible haematological neoplasm with clonal 
eosinophilia, initially by peripheral blood analysis for FIP1L1-PDGFRA by 
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fluorescence in situ hybridisation (FISH) or nested reverse transcriptase 
polymerase chain reaction (RT-PCR) (Grade 1C). 
 Serum tryptase estimation should be performed if the differential diagnosis 
includes chronic eosinophilic leukaemia or systemic mastocytosis (Grade 1B).  
 In the absence of an identifiable cause and with negative peripheral blood 
analysis for FIP1L1-PDGFRA by FISH or nested RT-PCR, a bone marrow 
aspirate, trephine biopsy and cytogenetic analysis should be performed; the 
possibility of an underlying lymphoma or of the lymphocytic variant of 
hypereosinophilic syndrome should be evaluated, including consideration of 
immunophenotyping of peripheral blood and bone marrow lymphocytes and 
analysis for T-cell receptor gene rearrangement (Grade 1C). The possibility 
of systemic mastocytosis or other myeloid neoplasm should be considered. 
Assessment of tissue damage 
In patients with suspected tissue damage as a consequence of eosinophilia, investigations 
are directed at assessment of organ involvement including chest radiography and/or 
computed tomography (CT) of the thorax, echocardiography, serum troponin T and 
pulmonary function testing (see Table VII). An unprovoked thromboembolic event is a 
recognised consequence of hypereosinophilia and is a manifestation of tissue damage. 
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In patients found to have tissue damage, the frequency of further serial evaluations of 
organ function is determined by the severity and extent of organ compromise and/or by 
worsening of the eosinophilia 
Key recommendations 
Assessment for possible eosinophil-associated end organ damage 
 End organ damage should be assessed using chest radiography and/or 
computed tomography (CT) of the thorax, echocardiography, serum 
troponin T and pulmonary function testing. (Grade 1C). 
 An unprovoked thromboembolic event should be recognised as a possible 
manifestation of eosinophil-associated tissue damage (Grade 2C). 
 In patients with end organ damage, the frequency of further serial 
evaluations of organ function should be determined by the severity and 
extent of organ compromise and/or by worsening of the eosinophilia (Grade 
2C). 
Treatment of patients with eosinophilia 
The treatment of eosinophilia should be directed at the underlying cause. Specific 
treatment of secondary (reactive) eosinophilia is outside of the scope of this guideline and 
specialist referral should be made where indicated. Emergency treatment, treatment of 
clonal eosinophilia and treatment of idiopathic HES are dealt with below.  
Emergency treatment 
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There is no consensus on the absolute eosinophil level in the peripheral blood at which 
treatment is deemed necessary in completely asymptomatic patients (Gotlib 2014). The 
absolute eosinophil count does not correlate well with the degree or risk of organ damage 
(Brito-Babapulle 2003; Flaum et al, 1981; Schooley et al, 1981). There is some evidence 
for urgent treatment in cases with a high count of degranulated eosinophils since cardiac 
damage has been found to correlate with a degranulated eosinophil count of 1 × 109/l or 
more (Spry et al, 1983). In the absence of identified organ damage, there is no evidence 
to indicate when or if treatment should be initiated.  However in cases with significant 
organ dysfunction, particularly cardiac or pulmonary, emergency treatment is required. 
The aim of therapy is to reduce the absolute eosinophil count and reduce tissue 
infiltration and eosinophil-mediated tissue damage (Klion 2009). A response assessment 
has been proposed by the Nordic study group based on (i) normalisation of eosinophil 
count,  other haematological parameters and biochemical indicators such as IgE and 
serum tryptase; (ii) no evidence of organ involvement or symptoms; (iii) quality of life 
assessment (Bjerrum et al, 2012). This has yet to be validated. 
Corticosteroids 
High dose corticosteroids are the mainstay of emergency treatment and may be indicated 
whilst awaiting the results of initial investigations. The evidence for their use is limited 
and largely restricted to numerous case reports and small case series, many of which were 
published prior to the understanding of the molecular characterisation of 
hypereosinophilic syndromes (Klion et al, 2006; Roufosse & Weller 2010; Simon & 
Klion 2012; Weller & Bubley 1994). Although there is no evidence for the use of 
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corticosteroids in combination with other immunosuppressive or myelosuppressive 
agents as first line therapy, this may be prudent to lessen eosinophil-mediated tissue 
damage.  
Where there is evidence of life-threatening organ involvement treatment should start with 
the equivalent of 1 mg/kg/day of methylprednisolone intravenously. Otherwise, oral 
prednisolone is generally used at a dose of 0.5–1 mg/kg/day for 1‒2 weeks. In extreme 
eosinophilia, consideration could be given to the concomitant administration of 
allopurinol for a short period. Corticosteroids can be slowly tapered over a period of 2‒3 
months to the lowest possible maintenance dose to retain response. Complete and partial 
response rates vary, typically between 64 and 85% (Helbig et al, 2013; Helbig et al, 2014; 
Ogbogu et al, 2009) with reported maintenance doses of prednisone (or equivalent) 
ranging widely between 1 mg and 60 mg daily for periods between 2 months and 20 
years. The toxicity of long-term corticosteroids needs to be considered, and measures 
should be taken to limit the risk. In patients with a strong possibility of strongyloides 
exposure (see Table III), concomitant empirical ivermectin therapy should be given (200 
μg/kg/day for 2 days) to prevent potentially fatal hyperinfection (Ramanathan & Nutman 
2008). 
Steroid-unresponsive cases may require alternative therapeutic approaches and it has 
been proposed that in cases where the eosinophil count remains greater than 1.5 × 109/l 
after one month of therapy or if a patient requires a maintenance dose of prednisolone (or 
equivalent) of greater than 10 mg daily a second-line agent should be considered (see 
Treatment of idiopathic hypereosinophilic syndrome).
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Key recommendations 
Emergency treatment  
 Patients requiring emergency treatment for severe or life-threatening 
eosinophilia should receive high-dose corticosteroids (Grade 1B). 
 Patients receiving corticosteroids, in whom there is a risk of strongyloides 
infection, should receive concomitant ivermectin to prevent potentially fatal 
hyperinfection (Grade 1B) 
Treatment of primary (clonal) eosinophilic disorders 
Chronic leukaemias with clonal eosinophilia and a specific molecular target  
In clonal eosinophilia the highest priorities are to provide emergency treatment when 
required and to recognise entities in which specific therapy with a tyrosine kinase 
inhibitor (TKI) is indicated as highlighted in Table VI. Patients with significant organ 
dysfunction, particularly cardiac or pulmonary, require emergency corticosteroid 
treatment alongside specific TKI therapy when appropriate.
Cases associated with FIP1L1-PDGFRA are highly sensitive to imatinib and a starting 
dose of 100 mg daily should be commenced (Baccarani et al, 2007). Dose titration, up to 
400 mg daily, is dependent on eosinophil count and molecular response. Imatinib should 
also be commenced in patients presenting in acute leukaemic transformation as they may 
enter remission with imatinib even in the absence of chemotherapy (Barraco et al, 2014).  
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Acquired imatinib resistance is uncommon but a T674I mutation, and less commonly a 
D842V mutation, leading to multi-TKI resistance has been observed in some cases.  
Cases associated with PDGFRB rearrangement or an ETV6-ABL1 fusion gene are 
responsive to imatinib at a dose of 400 mg daily. Molecular monitoring is indicated. 
Neoplasms associated with ETV6-FLT3 may be responsive to sunitinib or sorafenib 
(Walz et al, 2011).
Ruxolitinib has demonstrated activity in cases with PCM1-JAK2 or other JAK2
rearrangement. Doses are adapted to platelet counts in line with the summary of product 
characteristics for ruxolitinib. Although a complete remission may be achieved, this is 
often of limited duration (Schwaab et al, 2014). 
Chronic leukaemias with clonal eosinophilia without a specific molecular target  
Clonal disorders without a specific molecular targeted therapy can be treated as for 
idiopathic HES as described below. Occasional patients have responded to imatinib and 
in view of the good safety profile of this agent, a short trial (4‒6 weeks) is justified. 
Patients with at least four features of an MPN are more likely to respond to imatinib 
(Khoury et al, 2016). Cases associated with FGFR1 rearrangement have a poor prognosis 
and intensive AML-type induction treatment followed by haematopoietic stem cell 
transplantation (HSCT) may be the best option. Because of the poor prognosis of CEL, 
NOS (Helbig 2012) this approach could also be justified in these cases. Response is 
assessed by monitoring a clonal marker when possible and by the eosinophil count. 
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Other haematological malignancies with an associated clonal eosinophilia 
Patients with AML with clonal eosinophilia and no identifiable molecular or cytogenetic 
abnormality should be offered standard AML induction therapy. In patients with other 
haematological neoplasms with an associated clonal eosinophilia, treatment should be 
directed towards management of the underlying cause. If there is organ damage or 
dysfunction relating to the eosinophilia, addition of corticosteroids is indicated. 
Key recommendations 
Treatment of clonal eosinophilia 
 Patients with clonal eosinophilia with FIP1L1-PDGFRA (including patients 
presenting with acute leukaemia), should be treated with low dose imatinib 
(Grade 1B). 
 Patients with clonal eosinophilia with PDGFRB rearrangement or ETV6-
ABL1 fusion should receive standard dose imatinib (Grade 1B). 
 Patients with clonal eosinophilia with ETV6-FLT3 fusion should be 
considered for sunitinib or sorafenib therapy (Grade 2B) 
 Patients with clonal eosinophilia with JAK2 rearrangement should be 
considered for ruxolitinib therapy (Grade 2B) 
 Patients with acute myeloid leukaemia (AML) with clonal eosinophilia and 
no molecular or cytogenetic abnormality suggesting likely response to a 
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tyrosine kinase inhibitor  should be offered standard AML induction therapy 
(Grade 1A). 
 Patient with other haematological neoplasms with clonal eosinophilia should 
have treatment directed at management of the neoplasm. If there is organ 
damage or dysfunction relating to the eosinophilia, treatment with 
corticosteroids should also be given (Grade 1C). 
Treatment of Lymphocyte variant HES 
Appropriate management is similar to that of idiopathic HES (see under relevant heading). 
Corticosteroids are indicated for primary management. Ciclosporin may be useful as a 
steroid-sparing agent and mepolizumab has shown efficacy in this setting (Ogbogu et al,
2009; Rothenberg et al, 2008). 
Key recommendations 
Treatment of lymphocytic variant of hypereosinophilic syndrome 
 Patients with the lymphocytic variant of HES can be managed in the same 
manner as idiopathic HES (grade 2B) 
Treatment of idiopathic hypereosinophilic syndrome 
Corticosteroids 
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In general, corticosteroids are the first-line therapy for idiopathic HES, and 
immunomodulatory and myelosuppressive agents are reserved for steroid-unresponsive 
disease or are used as adjuvant steroid-sparing therapy. 
Imatinib 
As in cases of clonal eosinophilia without a specific molecular target, patients with 
idiopathic HES failing first line corticosteroids should be considered for a short trial (4‒6 
weeks) of low dose imatinib given the good safety profile of this agent.  
Immunomodulatory agents 
Interferon-alpha: Interferon-alpha targets both eosinophils and T cells making it a 
rational therapy for many hypereosinophilic disorders. Its mechanism of action and role 
in the treatment of hypereosinophilic syndromes including idiopathic HES have been 
extensively reviewed (Butterfield 2005).  
Improvement in the eosinophil count is associated with improvement in organ 
dysfunction including clinical symptoms and organomegaly (hepatomegaly, 
splenomegaly or both) (Fruehauf et al, 1993; Murphy et al, 1990; Zielinski & Lawrence 
1990), cardiopulmonary effects (Yamada et al, 1998), mucosal ulcers (Barouky et al,
2003) and cutaneous manifestations  (Mohr et al, 1995). It may take several weeks to 
achieve a response.  
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The optimal starting dose of interferon-alpha in hypereosinophilic disorders has yet to be 
defined. A wide variety of effective doses have been reported between 1 and 5 million 
units/m2/day (Butterfield 2005). The side effects are usually dose dependent and 
frequently dose limiting (Ogbogu et al, 2009). Maintenance doses may be lower than 
initiation doses (Busch, et al, 1991; Canonica et al, 1995). There are limited data on the 
efficacy of once weekly pegylated-interferon as an alternative to conventional interferon-
alpha (Butterfield & Weiler 2012). 
Ciclosporin: ciclosporin is a calcineurin inhibitor, is used primarily in HES as a steroid-
sparing immunosuppressive agent despite a relative paucity of published information, 
largely limited to case reports. Ciclosporin impairs T-cell activation hence its value in 
lymphocyte-variant HES. There are also reports of sustained clinical responses when 
ciclosporin is added to prednisolone in previously steroid-resistant idiopathic HES 
(Akiyama et al, 1997; Fukuta et al, 2001, Zabel & Schlaak 1991), when used as a steroid-
sparing agent in idiopathic paediatric HES (Hosoki et al, 2011; Nadarajah et al, 1997) 
(and also in cases of eosinophilic cellulitis and fasciitis (Kim et al, 2013, Tahara et al,
2008)).  
A variety of effective ciclosporin doses have been reported, generally with gradual 
tapering following clinical response. The largest published experience in HES is that of 
11 patients (within a 188-patient retrospective case series) who received ciclosporin at 
doses of 150‒500 mg/24 hrs (median 200 mg); of the 5 patients who received ciclosporin 
monotherapy, 1 patient achieved a complete response with 2 partial responders although, 
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notably, ciclosporin was discontinued early in 9 of the 11 patients, due to either lack of 
efficacy or poor tolerance (Ogbogu et al, 2009). 
Azathioprine: azathioprine is a purine analogue used commonly in combination with 
corticosteroids as a steroid-sparing agent. There are case reports of its use in 
hypereosinophilic syndromes particularly in those presenting with cardiological 
complications including endomyocardial fibrosis (Pineton de Chambrun et al, 2015) and 
eosinophilic myositis (Aggarwal et al, 2001; Fozing et al, 2014). The recommended 
starting dose is 1‒3 mg/kg/day and this should be adjusted, within these limits, depending 
on the clinical and haematological response. This may not be evident for weeks or 
months. Lower starting doses should be considered in patients with renal and/or hepatic 
insufficiency or those receiving concomitant allopurinol. 
Myelosuppressive therapy 
Hydroxycarbamide:  hydroxycarbamide is a non-alkylating ribonucleotide reductase 
inhibitor, which has been used as a myelosuppressive agent at dose of 0.5 to 3 g daily to 
lower the eosinophil count as a corticosteroid-sparing agent either alone (Ogbogu et al,
2009) or in combination with interferon (Butterfield 2005).  
Other myelosuppressive therapy: haematological benefit has been observed with other 
agents such as vincristine, cyclophosphamide, etoposide, cladribine and cytarabine but 
the evidence for their use is limited (Gotlib 2014).   
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Monoclonal antibodies  
Anti-interleukin 5 monoclonal antibodies: interleukin 5 is the primary cytokine involved 
in eosinophil development and is frequently elevated in patients with HES (Owen et al, 
1989). Two monoclonal anti-IL5 antibodies have shown promising efficacy: 
mepolizumab, a fully humanised murine antibody, and reslizumab, a humanised rat 
antibody.  
Mepolizumab has shown efficacy in steroid-refractory (Plotz et al, 2003) and steroid-
dependent HES (Ogbugu et al, 2009; Rothenberg et al, 2008).  Roufosse et al (Roufosse
et al, 2010; Roufosse et al, 2013) reported that patients receiving the highest doses of 
prednisolone at the outset responded better to mepolizumab than those on lower doses. 
However patients with the greatest fall in eosinophil counts did not experience fewer 
HES-related symptoms. The drug was well tolerated. There is currently no evidence on 
its effectiveness in improving end-organ damage in HES. 
There are fewer data on reslizumab. Klion et al (Klion et al, 2004) found that two of four 
HES patients responded to monthly reslizumab infusions but relapsed following cessation 
of therapy. Response was not predicted by FIP1L1-PDGFRA status or baseline IL5 levels. 
Alemtuzumab: two initial reports indicate that alemtuzumab may induce clinical and 
haematological remissions in patients with HES unresponsive to steroids, 
hydroxycarbamide, interferon and imatinib (Pitini et al, 2004; Sefcick et al, 2004; Strati, 
et al, 2013).  Patients relapsing after therapy may achieve durable responses following re-
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treatment with alemtuzumab. The principal complications were infections (including 
cytomegalovirus reactivation) and infusion reactions. Two case reports suggest that 
alemtuzumab can reverse established cardiac and cerebral dysfunction in patients with 
FIP1L1-PDGFRA-negative HES (Perini et al, 2009; Sye et al, 2012). 
Key recommendations 
Treatment of idiopathic hypereosinophilic syndrome 
 Patients with idiopathic hypereosinophilic syndrome (idiopathic HES) should 
be treated in the first instance with corticosteroids (see emergency treatment 
above). 
 Patients with idiopathic HES who do not respond adequately to 
corticosteroids, or who require prolonged corticosteroid therapy, or who are 
intolerant of corticosteroids, should be considered for a short trial (4‒6 weeks) 
of imatinib, immunomodulatory agents (interferon alpha, ciclosporin or 
azathioprine), myelosuppressive therapy (hydroxycarbamide) or monoclonal 
antibody therapy with mepolizumab (anti-interleukin 5), the latter 
preferably as part of a clinical trial (Grade 2B).  
 Alemtuzumab, an anti-CD52 monoclonal antibody, should be considered for 
patients with severe idiopathic HES unresponsive to other therapies, and 
may be useful in patients with idiopathic HES-associated cardiac and 
cerebral dysfunction. (Grade 2B) 
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Role of haematopoietic stem cell transplantation (HSCT):
Allogeneic HSCT has been performed in a small number of patients with refractory or 
debilitating HES that was idiopathic or ill-defined and prolonged remissions have been 
reported (Cooper et al, 2005; Ueno et al, 2002). A lack of clinical trials, small numbers 
reported and clinical heterogeneity make it impossible to offer definitive 
recommendations. Although both myeloablative and reduced intensity conditioning 
regimens have been used, there remains insufficient evidence to give recommendations 
on conditioning regimen or intensity (Cooper et al, 2005; Halaburda et al, 2006; Juvonen
et al, 2002; Ueno et al, 2002). 
Cases of eosinophilia associated with FGFR1 rearrangement have a poor prognosis and 
intensive AML-type induction treatment followed by HSCT may be the best option. 
Because of the poor prognosis of CEL, NOS (Helbig 2012) this approach could also be 
justified in these cases.  
HSCT should also be considered for those HES patients refractory to or intolerant of both 
conventional TKI therapy and experimental medical therapy, where available, or who 
display progressive end organ damage (Fathi et al, 2014).  
Key recommendations 
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Role of haemopoietic stem cell transplantation (HSCT) 
 HSCT should be considered for cases with clonal eosinophilia with FGFR1
rearrangement, patients with chronic eosinophilic leukaemia, not otherwise 
specified and those HES patients refractory to or intolerant of both 
conventional tyrosine kinase inhibitor (TKI) therapy and experimental 
medical therapy, where available, or who display progressive end organ 
damage. (Grade 2C) 
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Table I. Evidence statements and grades of recommendations. 
GRADE nomenclature 
STRENGTH OF RECOMMENDATIONS: 
Strong (grade 1): Strong recommendations (grade 1) are made when there is 
confidence that the benefits do or do not outweigh harm and burden. Grade 1 
recommendations can be applied uniformly to most patients. Regard as 
'recommend'. 
Weak (grade 2): Where the magnitude of benefit or not is less certain a weaker 
grade 2 recommendation is made. Grade 2 recommendations require judicious 
application to individual patients. Regard as ‘suggest’.
QUALITY OF EVIDENCE 
The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in 
context it is useful to consider the uncertainty of knowledge and whether further 
research could change what we know or our certainty. 
(A) High Further research is very unlikely to change confidence in the estimate of 
effect. Current evidence derived from randomised clinical trials without important 
limitations. 
(B) Moderate Further research may well have an important impact on confidence in 
the estimate of effect and may change the estimate. Current evidence derived from 
randomised clinical trials with important limitations (e.g. inconsistent results, imprecision 
wide confidence intervals or methodological flaws e.g. lack of blinding, 
large losses to follow up, failure to adhere to intention to treat analysis), or very 
strong evidence from observational studies or case series (e.g. large or very large 
and consistent estimates of the magnitude of a treatment effect or demonstration of 
a dose-response gradient). 
(C) Low Further research is likely to have an important impact on confidence in the 
estimate of effect and is likely to change the estimate. Current evidence from 
observational studies, case series or just opinion. 
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Table II   Causes of eosinophilia 
A. Secondary (reactive) eosinophilia 
 Allergic disorders 
- Asthma 
- Atopic dermatitis/eczema 
- Seasonal allergic disorders (rhinitis syndromes/hayfever) 
 Dermatological disorders (non-allergic) 
- Wells syndrome 
 Drugs 
- Including antibiotics, anticonvulsants  
 Infectious diseases 
- Parasitic infections* 
- Fungal infections* 
 Gastrointestinal disorders 
- Primary gastrointestinal eosinophilic disorders including eosinophilic 
oesophagitis 
- Chronic pancreatitis  
- Inflammatory bowel disease 
- Coeliac disease 
 Vasculitides  
- Polyarteritis nodosa  
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) 
 Rheumatological disease 
- Systemic lupus erythematosus 
- Eosinophilic fasciitis (Shulman disease)  
- Rheumatoid Arthritis 
 Respiratory disease 
- Löffler syndrome 
- Allergic bronchopulmonary aspergillosis 
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- Sarcoidosis 
 Neoplasms (non-haematological and haematological in which the eosinophils are 
not part of the neoplastic clone)  
- Solid tumours  
- Lymphomas and acute lymphoblastic leukaemia (the majority of cases in 
which the eosinophils are non-clonal)  
- Systemic mastocytosis†
 Lymphocytic variant hypereosinophilic syndrome 
 Miscellaneous causes 
- Atheroembolic disease 
- Chronic graft-versus-host disease 
- Gleich's syndrome (episodic angio-oedema with eosinophilia) 
B Primary (clonal) eosinophilia
 Haematological neoplasms with clonal eosinophilia (i.e. neoplasms where the 
eosinophils form part of the neoplastic clone) 
- Myeloid and lymphoid neoplasms with rearrangement of PDGFRA, 
PDGFRB or FGFR1 or with PCM1-JAK2, ETV6-JAK2 or BCR-JAK2
-  Chronic eosinophilic leukaemia, not otherwise specified (CEL, NOS) 
including cases with ETV6-ABL1, ETV6-FLT3 or other tyrosine kinase 
fusion genes 
- Atypical chronic myeloid leukaemia with eosinophilia (aCML-Eo) 
- Chronic myelomonocytic leukaemia with eosinophilia (CMML-Eo) 
- Chronic myelogenous leukaemia in accelerated phase or transformation 
(occasional cases) 
- Other myeloproliferative neoplasm in transformation (occasional cases) 
- Acute myeloid leukaemia with eosinophilia, particularly with 
t(8;21)(q22;q22.1) or inv(16)(p13.1q22) (occasional cases only) (AML-
Eo) 
- Acute lymphoblastic leukaemia, only if eosinophils demonstrated to be 
part of the neoplastic clone  
- Systemic mastocytosis†
C Idiopathic eosinophilia 
 No detectable primary or secondary causes for eosinophilia 
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* In the presence of opportunistic or unusual infections, concomitant HIV infection 
should be considered. 
† Systemic mastocytosis – the eosinophilia may be clonal, cytokine driven or a 
combination of both 
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Table III. Infectious diseases associated with eosinophilia* 




Travel to the tropics: South and 
Central America, sub-Saharan 
Africa, South Asia, Southeast
Asia
Skin: localized, pruritic, 
erythematous papular rash at site 
of skin penetration; or rapidly 
migrating pruritic rash (cutaneous 
larva migrans); or generalised 
rash
GI: abdominal pain, weight loss, 
diarrhoea, vomiting
Lung: cough, wheeze, dyspnoea, 
haemoptysis
Usually asymptomatic. A raised 
absolute eosinophil count may be 
the only feature (but 
immunosuppression can make the 
eosinophil count falsely normal) 
Serology (ELISA): generally 
sensitive and specific, but false 
negatives possible in 
immunocompromised patients.
Fresh stool microscopy: relatively 
insensitive as parasitic larvae are 
only present intermittently.
In rare cases, microscopy of sputum 
bronchoalveolar fluid may be 
useful.
Check serology in all travellers 
with suggestive clinical features 
arriving from an endemic region
and before starting steroids or 
immunosuppression in all patients 
with a history of living in an 
endemic region. If positive, treat 
strongyloidiasis before starting 







Travel to endemic area (mostly 
rural tropical and subtropical 
areas of Asia, sub-Saharan Africa, 
and Latin America).
Often asymptomatic.
GI: diarrhoea, vomiting, 
abdominal pain, iron-deficiency, 
malnutrition.
Fresh stool microscopy for eggs 
(may need repeating if negative)
Filariasis Travel to endemic area (mainly 
tropics)
Severe pruritus and /or corneal 
Serology











Transient subcutaneous swellings 
(Loa loa)
Lymphoedema (W. bancrofti or B. 
malayi)
Eosinophilia may be only feature





Travel to endemic area (mainly 
tropics), more common in 
children
GI: ascending cholangitis, 
obstructive jaundice, bile duct 
perforation, bowel obstruction (all 
rare)
Lung: cough, wheeze, dyspnoea, 
haemoptysis
Fresh stool microscopy for eggs 
and larvae
Abdominal radiograph showing 
dilated bowel; worm aggregates 
may be visible as a ‘whirlpool’ 
shadow.
Ultrasonography may demonstrate 
hepatobiliary or pancreatic 
ascariasis
Toxocariasis
(Toxocara canis or, 
less commonly, 
Toxocara cati)
Contact with domestic dogs or 
cats.
Usually asymptomatic; may cause 
fever and anorexia.
Rarely causes visceral larva 
migrans (hepatitis and 
pneumonitis), or ocular, 





Ingestion of undercooked pork (or 
rarely other meats) several days 
before onset of symptoms.
May be asymptomatic, or cause 
fever, headache, vomiting and 
diarrhoea.
Musculoskeletal (due to invasion 
of muscle by parasite): myositis, 
Serology (ELISA, latex 
agglutination) – may be false 
negative in first 3-4 weeks of 
infection. 
Occasionally Western blot on blood 
or muscle biopsy may be needed.
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weakness, muscle swelling 
including peri-orbital oedema. 
May affect heart and respiratory 
muscles, or rarely lungs and CNS.
Schistosomiasis
(schistosoma spp.) 
Travel to endemic area (typically 
sub-Saharan Africa, South 
America, and east Asia), with 
history of freshwater swimming.
Acute symptoms: localised 
dermatitis (‘swimmer’s itch’), 
fever, myalgia, headache, dry 
cough, diarrhoea, and abdominal 
pain.
S. mansoni:  hepatosplenomegaly 
and portal hypertension.
S. haematobium: genitourinary: 
haematuria, squamous cell 
carcinoma, obstructive uropathy
Rarely neurological symptoms 
due to ectopic eggs in brain or 
spinal cord. 
Eosinophilia may be only 
manifestation
Urine and fresh stool microscopy 
(low sensitivity in low-level disease 
or in early infection).
Serology








Background of asthma or cystic 
fibrosis
Lung: cough, wheeze, fever, 
dyspnoea, expectoration of brown 
mucus plugs, haemoptysis, lobar 
consolidation.
Wide range of other symptoms 
invasive aspergillosis, especially 
in immunocompromised patients.
CT of lungs: bronchiectasis or lung 
infiltrates in ABPA; classically 
cavitating nodules surrounded by 
ground-glass infiltrates or lobar 
consolidation in invasive 
aspergillosis.
ABPA: skin prick test reactivity to 
aspergillus antigens and serum 
antibodies to aspergillus spp, serum 
total IgE.
Invasive aspergillosis: fungal 
culture of respiratory samples; 





May be asymptomatic. Travel to 
desert areas, especially in northern 
and central America.
Symptoms of pneumonia, 
followed by prolonged arthralgia, 
fever, erythema nodosum
Serology.
Culture of respiratory specimens, or 
lung biopsy, +/- PCR.
Fascioliasis
(Fasciola hepatica)
Usually follows ingestion of 
watercress grown in sheep-raising 
areas, but may also be transmitted 
via water lettuce, mint and khat 
(common in some Somali 
communities).
GI: right upper quadrant pain, 
vomiting, jaundice (may be mild 
initially, with extreme 
eosinophilia).
Serology
Abdominal ultrasound or CT may 
show liver tracks or abscesses).
Scabies
(Sarcoptes scabiei)
Widespread, intensely pruritic 
rash, often worse at night. 
Erythematous papules.
Other family members may be
affected
Skin scrapings or dermoscopic 
examination
Footnote 
* Consider the need to test for human immunodeficiency virus (HIV) or human 
lymphotropic virus 1 (HTLV-1) in patients with probable opportunistic infections 
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; CNS, central nervous 
system; CT, computed tomography; ELISA, enzyme-linked immunosorbent assay; GI, 
gastrointestinal; PCR, polymerase chain reaction
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Table IV. Primary gastrointestinal disorders associated with gastrointestinal tissue 
eosinophilia with or without peripheral blood eosinophilia 
Disorder General Comments
Primary gastrointestinal eosinophilic 
disorders
1) Primary eosinophilic oesophagitis
2) Primary eosinophilic gastritis
3) Primary eosinophilic colitis
A myriad of clinical symptoms may be present 
depending on which segment of the gastrointestinal 
tract is involved. These may include fatigue, 
dysphagia, weight loss, vomiting, gastric dysmotility 
or diarrhoea.  The peripheral blood eosinophil count 
is not always abnormal. Diagnosis involves 
comprehensive history and examination, evaluation 
of secondary causes of gastrointestinal eosinophilia 
and biopsy findings (Prussin 2014; Zuo &
Rothenburg 2007). 
Chronic Pancreatitis Can be associated with peripheral blood eosinophilia. 
Incidence is higher in autoimmune pancreatitis than 
in non-autoimmune causes (Wang et al, 2009)
Inflammatory Bowel Disease Both ulcerative colitis and Crohn disease can be 
associated with peripheral blood eosinophilia. 
Ulcerative colitis with eosinophilia may be 
associated with a more severe clinical phenotype,
including primary sclerosing cholangitis (Barrie et al, 
2013; Suttor et al, 2009).
Coeliac Disease Can be associated with eosinophilic oesophagitis
(Thompson et al, 2012)
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Table V. Suggested investigations to evaluate the cause of eosinophilia 
In all cases of eosinophilia:  Full blood count and blood film   Routine biochemical tests including renal and liver function tests, bone 
profile, lactate dehydrogenase   Erythrocyte sedimentation rate and/or C-reactive protein. 
In patients who are otherwise well with mild to moderate eosinophilia between 0.5 and 
1.5 × 109/l, further testing may not be indicated. 
Patients with systemic symptoms or those with persistent eosinophilia (at least 1.5 × 
109/l), with or without suspected organ damage, should be investigated for possible 
secondary causes with the following: 
In those with a suspected allergic aetiology: 
• Serum total immunoglobulin E (IgE) 
• Allergen-specific IgE tests 
• Skin-prick testing for specific allergies. 
In those with a suspected non-allergic dermatological cause: 
• Skin biopsy 
In those with a suspected infectious cause: 
• Fresh stool for parasites 
• Serological tests for suspected parasitic infections e.g. strongyloidiasis, 
schistosomiasis, filariasis, toxocariasis where appropriate. (see table 3) 
• Urine examination for schistosome eggs where appropriate 
• Consider HIV testing if atypical parasitic or fungal infection 
In those with a suspected gastrointestinal cause: 
• Upper gastrointestinal endoscopy, small bowel endoscopy and/or 
colonoscopy/sigmoidoscopy 
• Serum amylase 
• Serology for coeliac disease-related autoantibodies (anti-tissue 
transglutaminase) 
In those with a suspected connective tissue disorder 
• Antinuclear activity (ANA) or anti-double stranded DNA (dsDNA) 
antibodies 
• Antibodies to cyclic citrullinated peptide (CCP) 
In those with a suspected vasculitis: 
• Antineutrophil cytoplasmic antibodies (ANCA) 
Formatted: German (Germany)
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• Serology for hepatitis B virus (HBV), hepatitis C virus (HCV),  human 
immunodeficiency virus (HIV), cytomegalovirus (CMV) and parvovirus 
B19 
In those with suspected respiratory disease: 
• Appropriate imaging  
• Bronchoscopy with bronchoalveolar lavage/endobronchial 
ultrasonography 
In those with a suspected lymphoma, non-haematological malignancy or T-cell 
driven eosinophilia: 
• Appropriate imaging and tissue biopsy 
• Peripheral blood T-cell immunophenotyping and T-cell receptor gene 
rearrangement studies  
Miscellaneous: 
• Tests for atheroembolic disease. 
• Immunoglobulins and C1 esterase levels* 
* If the differential diagnosis includes Gleich’s syndrome
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Table VI. Cytogenetic and molecular abnormalities associated with primary 
eosinophilias  
Cytogenetic abnormality Molecular abnormality Clinical significance
Usually none but rarely a 
translocation with a 4q12 
breakpoint or a 
cytogenetic abnormality 
unrelated to the causative 
molecular lesion  




other translocation with a 
5q31~q33 breakpoint
ETV6-PDGFRB* fusion or 
other rearrangement of 
PDGFRB
Imatinib sensitive
t(8;13)(p11;q12) or other 
translocation with an 
8p11-12 breakpoint
ZMYM2-FGFR1 (previously 
known as ZNF198-FGFR1) or 
other rearrangement of 
FGFR1
Poor prognosis, 
investigational drugs or 
haematopoietic cell 
transplantation to be 
considered
t(8;9)(p22;p24) or other 
translocation with an 9p24
breakpoint
PCM1-JAK2 or other 
rearrangement of JAK2
Ruxolitinib sensitive
t(12;13)(p13;q12) ETV6-FLT3 Sunitinib and sorafenib 
sensitive
t(9;12)(q34;p13) ETV6-ABL1 Imatinib sensitive
* some cases with a t(5;12)(q31~q33;p12) have an out of frame fusion between ETV6 and 
ACSL6 (formerly known as ACS2) that is not responsive to imatinib (Cools et al, 2002). 
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Table VII. Assessment of End-Organ Damage 
Cardiac assessment:  chest radiography, electrocardiogram, echocardiogram, serum 
troponin T 
Pulmonary assessment:  pulmonary function tests including spirometry, O2 saturation 
and transfer factor of the lung for carbon monoxide (TLCO) 
Footnote:  
If there is a strong suspicion of cardiac dysfunction in the absence of obvious 
echocardiographic abnormalities, a specialist cardiology review should be sought.  
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Figure 1. Testing algorithm for possible haematological neoplasms with clonal 
eosinophilia 
 Eosinophilia (eosinophil count at least 1.5 ×
109/l) with or without suspected organ damage No obvious underlying cause
Presence of reciprocal 
translocations involving 4q12 
(PDGFRA), 5q31-33 (PDGFRB), 
8p11-12 (FGFR1), 9p24 (JAK2), 
13q12 (FLT3) or, potentially, loci 






• Peripheral blood analysis for FIP1L1-PDGFRA by FISH or
nested RT-PCR
• Serum mast cell tryptase
• Bone marrow aspirate, trephine biopsy and cytogenetic
analysis
Myeloid and lymphoid 
neoplasms with eosinophilia and 
abnormalities of PDGFRA, 
PDGFRB, FGFR1 or JAK2
or





RT-PCR and sequence 
confirmation of any fusion 
suspected by cytogenetic 
analysis
Yes
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